Demographic characteristics and medications
| Age, years* | 52.4 (10.2) |
| Disease duration, years* | 9.5 (6.6) |
| Body mass index, kg/m2* | 28.3 (4.3) |
| Female, n (%) | 71 (50.4) |
| Current smokers, n (%) | 24 (17) |
| Not performing physical exercise, n (%) | 63 (44.7) |
| Erosive disease on X-ray of hands and feet, n (%) | 38 (26.6) |
| C reactive protein, mg/L† | 2 (0–63) |
| Erythrocyte sedimentation rate, mm† | 13 (2–64) |
| DAS28ESR† | 3.2 (0.6–6.4) |
| SDAI† | 8.6 (0.1–39.5) |
| Current use of NSAIDs, n/total (%) | 45/139 (32.4) |
| Current use of steroids, n (%) | 15 (10.6) |
| Mean (SD), mg daily dose among users | 4.4 (1.2) |
| Current use of csDMARDs, n (%) | 81 (57.4) |
| Methotrexate, n (%) | 50 (35.5) |
| Leflunomide, n (%) | 29 (20.6) |
| Sulfasalazine, n (%) | 2 (1.4) |
| Current use of bDMARDs, n (%) | 46 (32.6) |
| Adalimumab, n (%) | 19 (13.5) |
| Etanercept, n (%) | 13 (9.2) |
| Golimumab, n (%) | 8 (5.7) |
| Infliximab, n (%) | 5 (3.5) |
| Certolizumab, n (%) | 1 (0.7) |
*Mean (SD).
†Median (range).
bDMARD, biological disease-modifying antirheumatic drug; csDMARD, conventional synthetic disease-modifying antirheumatic drug; DAS28ESR, 28-joint Disease Activity Score with erythrocyte sedimentation rate; NSAID, non-steroidal anti-inflammatory drug; SDAI, Simplified Disease Activity Index.